# Evommune News Releases

### Jun 29, 2026 8:30 am EDT
[Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria](https://ir.evommune.com/news-events/press-releases/detail/124/evommune-announces-top-line-results-from-evo756-phase-2b-trial-in-moderate-to-severe-chronic-spontaneous-urticaria)

### May 7, 2026 4:05 pm EDT
[Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights](https://ir.evommune.com/news-events/press-releases/detail/123/evommune-reports-first-quarter-2026-financial-results-and-provides-business-highlights)

### Apr 6, 2026 9:00 am EDT
[Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine](https://ir.evommune.com/news-events/press-releases/detail/122/evommune-to-host-kol-webinar-on-april-13-2026-highlighting-the-potential-of-mrgprx2-inhibition-in-migraine)

### Mar 5, 2026 4:01 pm EST
[Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights](https://ir.evommune.com/news-events/press-releases/detail/121/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights)

### Feb 12, 2026 8:30 pm EST
[Evommune Announces $125 Million Private Placement](https://ir.evommune.com/news-events/press-releases/detail/120/evommune-announces-125-million-private-placement)

### Feb 10, 2026 7:30 am EST
[Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis](https://ir.evommune.com/news-events/press-releases/detail/119/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis)

### Dec 11, 2025 4:05 pm EST
[Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update](https://ir.evommune.com/news-events/press-releases/detail/118/evommune-reports-third-quarter-2025-financial-results-and-provides-business-update)

### Nov 7, 2025 4:05 pm EST
[Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares](https://ir.evommune.com/news-events/press-releases/detail/117/evommune-announces-closing-of-its-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares)

### Nov 5, 2025 7:45 pm EST
[Evommune Announces Pricing of its Initial Public Offering](https://ir.evommune.com/news-events/press-releases/detail/116/evommune-announces-pricing-of-its-initial-public-offering)

### Oct 30, 2025 6:30 am EDT
[Evommune Announces Commencement of Initial Public Offering](https://ir.evommune.com/news-events/press-releases/detail/115/evommune-announces-commencement-of-initial-public-offering)